Neutral News Coverage Very Unlikely to Impact AbbVie (ABBV) Stock Price

Media stories about AbbVie (NYSE:ABBV) have trended neutral on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 6,000 news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a news impact score of 0.30 on their scale. InfoTrie also assigned news articles about the company an news buzz score of 2 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted AbbVie’s score:

Shares of ABBV stock traded up $1.06 during trading on Friday, hitting $88.79. The company had a trading volume of 9,167,944 shares, compared to its average volume of 7,158,657. The company has a current ratio of 0.80, a quick ratio of 0.71 and a debt-to-equity ratio of 8.70. The stock has a market cap of $126.68 billion, a price-to-earnings ratio of 15.86, a price-to-earnings-growth ratio of 0.79 and a beta of 1.62. AbbVie has a 52 week low of $77.50 and a 52 week high of $125.86.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.13. The company had revenue of $8.24 billion for the quarter, compared to analysts’ expectations of $8.23 billion. AbbVie had a net margin of 23.50% and a return on equity of 671.60%. AbbVie’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.41 earnings per share. As a group, sell-side analysts forecast that AbbVie will post 7.93 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be given a $1.07 dividend. This represents a $4.28 annualized dividend and a dividend yield of 4.82%. This is a boost from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. AbbVie’s dividend payout ratio is 68.57%.

Several equities research analysts have recently weighed in on ABBV shares. Piper Jaffray Companies reiterated a “hold” rating and set a $100.00 price target on shares of AbbVie in a research report on Friday, July 27th. BMO Capital Markets reiterated a “sell” rating and set a $78.00 price target on shares of AbbVie in a research report on Wednesday, August 22nd. Wolfe Research started coverage on AbbVie in a research report on Tuesday, October 23rd. They set an “underperform” rating on the stock. Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a research report on Monday, October 1st. Finally, Credit Suisse Group set a $85.00 price target on AbbVie and gave the company a “hold” rating in a research report on Friday, November 2nd. Five analysts have rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $103.68.

In related news, EVP Michael Severino sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 17th. The shares were sold at an average price of $97.52, for a total value of $4,876,000.00. Following the transaction, the executive vice president now directly owns 111,481 shares in the company, valued at $10,871,627.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.07% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/09/neutral-news-coverage-very-unlikely-to-impact-abbvie-abbv-stock-price.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

Read More: Why does a company issue an IPO?

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply